Göttingen, December 6, 2024 Michael Grosse to succeed Joachim Kreuzburg as Chief Executive Officer of Sartorius AG   Grosse to take over as Group CEO on July 1, 2025 At its meeting today, the Supervisory Board of Sartorius AG appointed Dr. Michael Grosse Chief Executive Officer of Sartorius. He will take over this position on July 1, 2025, from D [ … ]

Disclosure of inside information according to Article 17 MAR Michael Grosse to become Chief Executive Officer of Sartorius AG At its meeting today, the Supervisory Board of Sartorius AG resolved to appoint Dr. Michael Grosse as member of the Executive Board and Chief Executive Officer of the company with effect from July 1, 2025, for a term of th [ … ]

Göttingen, Germany | October 17, 2024 Nine-month results in line with expectations: sales revenue almost at prior-year level; orders on the rise; robust profitability; increased cash flow   Group sales revenue down only slightly by - 2.0 percent after nine months; order intake up 6.6 percent Underlying EBITDA margin reaches 27.7 percent; further i [ … ]

Göttingen, July 18, 2024 Half-year results: Moderately positive revenue development in the second quarter; demand recovery remains muted, full-year outlook deliberately more cautious; long-term trends remain positive   Sales revenue slightly down 2.2 percent after six months; growth of 3.6 percent in second quarter Underlying EBITDA margin at a  [ … ]

Disclosure of inside information according to Article 17 MAR Sartorius AG adjusts its guidance for fiscal year 2024 and presents results for H1 2024 In a continuously very challenging and volatile market environment, the life science group Sartorius closed the first half of the year with a positive trend in sales revenue development. In view of t [ … ]